<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346525</url>
  </required_header>
  <id_info>
    <org_study_id>GOAL: RHD RCT</org_study_id>
    <secondary_id>E.W. &quot;Al&quot; Thrasher Award</secondary_id>
    <nct_id>NCT03346525</nct_id>
  </id_info>
  <brief_title>Determining the Impact of Penicillin in Latent RHD: The GOAL Trial</brief_title>
  <acronym>GOAL</acronym>
  <official_title>The GOAL (GwokO Adunu pa Lutino) Trial: Determining the Impact of Penicillin on Latent Rheumatic Heart Disease: A Randomized Controlled Trial in Uganda</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Murdoch Children's Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Uganda Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karp Family Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gift of Life International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatic heart disease (RHD) affects at least 32.9 million people, mostly children living in
      low-resource settings. Long-term intramuscular benzathine penicillin G (BPG) prophylaxis is
      proven to prevent progression of chronic valve changes in patients with established rheumatic
      heart disease (RHD) and to allow regression of valve changes in patients with a history of
      acute rheumatic fever (ARF) with mild RHD. However, in low-resource settings ARF is an
      elusive diagnosis, and most patients (85%) are diagnosed only when RHD is severe and
      irreversible, medications ineffective, and surgical intervention is expensive and/or
      unavailable.

      Identification of latent RHD might be an opportunity to substantially reduce RHD morbidity
      and mortality. However, detection of latent RHD is only important if outcomes are improved.
      The appropriate management of children with latent RHD is unknown and no formal
      recommendations exist. While some clinicians prescribe penicillin prophylaxis for children
      with latent RHD, clinical equipoise exists regarding the best practice.

      To fill this gap, the investigators propose a randomized controlled trial in children with
      latent RHD to evaluate the efficacy of BPG prophylaxis compared to no prophylaxis. Our
      primary outcome measure is progression of valvular changes on echocardiogram at 2 years. A
      sample size of 916 children is needed to detect a 50% reduction of progression (expected
      range 7.5-12.5% progression in BPG-arm vs. 15%-25% progression in control-arm) with 90%
      power.

      AIM 1: To compare the proportion of children (aged 5-17 years) with latent RHD receiving BPG
      prophylaxis who progress to worse valvular disease at 2-years compared to children not
      receiving BPG prophylaxis.

      Hypothesis 1: Prophylaxis with BPG will result in fewer children with latent RHD showing
      progression of echocardiographic valve changes at 2 years compared to children with latent
      RHD not receiving BPG prophylaxis. (The investigators expect at least a 50% relative
      reduction in progression in the BPG arm: range 15%-25% control arm vs. 7.5-12.5% BPG-arm.)

      AIM 2: To compare the proportion of children (aged 5-17 years) with latent RHD receiving BPG
      prophylaxis who regress to improved valvular disease at 2-years compared to children not
      receiving BPG prophylaxis.

      Hypothesis 2: Prophylaxis with BPG will result in more children with latent RHD showing
      regression of echocardiographic valve changes by 2 years compared to children with latent RHD
      not receiving BPG prophylaxis. (The investigators expect at least a 50% relative increase in
      regression in the BPG arm: range 10-20% control arm vs. 20-40% BPG arm.)

      This study is highly significant because it will establish if BPG prophylaxis improves
      outcomes for children with latent RHD. Feasibility will be ensured through the experience,
      resources, community support, and accessible patient population of our investigational team.
      The results of our study will have high impact, immediately informing international policy on
      the standard of care for children diagnosed with latent RHD and shaping, over 2-3 years,
      practical and scalable programs that could substantially decrease the global burden of RHD.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression of valvular changes on echocardiogram at 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>To compare the proportion of children (aged 5-17 years) with latent RHD receiving BPG prophylaxis who progress to worse valvular disease at 2-years compared to children not receiving BPG prophylaxis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>regression of vavular changes on electrocardiogram at 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>To compare the proportion of children (aged 5-17 years) with latent RHD receiving BPG prophylaxis who regress to improved valvular disease at 2-years compared to children not receiving BPG prophylaxis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">916</enrollment>
  <condition>Rheumatic Heart Disease in Children</condition>
  <condition>Latent Rheumatic Heart Disease</condition>
  <condition>Rheumatic Heart Disease</condition>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>BPG Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular BPG prophylaxis (600,000 IU for children &lt;30kg, 1.2 million IU for children ≥30kg), every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intramuscular benzathine penicillin G (BPG) prophylaxis</intervention_name>
    <description>Intramuscular BPG prophylaxis (600,000 IU for children &lt;30kg, 1.2 million IU for children ≥30kg), every 28 days.</description>
    <arm_group_label>BPG Arm</arm_group_label>
    <other_name>benzathine penicillin G</other_name>
    <other_name>BPG</other_name>
    <other_name>penicillin prophylaxis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children will be eligible for study participation if they are (1) between the ages of
             5-17 years and (2) have a new diagnosis of latent RHD detected through primary school
             echo screening and confirmed by blinded consensus review. All children will be
             recruited from schools in Gulu District in Uganda.

        Exclusion Criteria:

          -  Patients will be excluded from the study for the following reasons:

               -  Known history of ARF or RHD

               -  Newly diagnosed RHD by echo screening consider to be &quot;missed clinical RHD&quot; as
                  compared to true latent RHD including: &gt; mild pathological valvular regurgitation
                  at the mitral valve or aortic valve, mitral stenosis (mean MV gradient ≥ 5mmHg)
                  (WHF, definite B), aortic stenosis (mean AV gradient ≥ 20mmHg)

               -  Structural or functional cardiac defects, other than those consistent with RHD,
                  that were known prior to or detected through echo screening (except patent
                  foramen ovale, small atrial septal defect, small ventricular septal defect, small
                  patent ductus arteriosus).

               -  Prior allergic reaction to penicillin

               -  Any known conditions predisposing to thrombocytopenia or hypercoagulability, or
                  other contraindications to intramuscular injection

               -  Any known co-morbid conditions (HIV, renal deficiencies, severe malnutrition
                  among others) that have resulted in prescription of regular antibiotic
                  prophylaxis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Beaton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Sarnacki</last_name>
    <phone>202-476-3586</phone>
    <email>rsarnack@cnmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Beaton, MD</last_name>
    <phone>202-476-3586</phone>
    <email>abeaton@cnmc.org</email>
  </overall_contact_backup>
  <reference>
    <citation>WHO - Global Burden of Disease. 2015;2015.</citation>
  </reference>
  <reference>
    <citation>Lue HC, Wu MH, Wang JK, Wu FF, Wu YN. Long-term outcome of patients with rheumatic fever receiving benzathine penicillin G prophylaxis every three weeks versus every four weeks. J Pediatr. 1994 Nov;125(5 Pt 1):812-6.</citation>
    <PMID>7965439</PMID>
  </reference>
  <reference>
    <citation>Tompkins DG, Boxerbaum B, Liebman J. Long-term prognosis of rheumatic fever patients receiving regular intramuscular benzathine penicillin. Circulation. 1972 Mar;45(3):543-51.</citation>
    <PMID>5012243</PMID>
  </reference>
  <reference>
    <citation>Zhang W, Mondo C, Okello E, Musoke C, Kakande B, Nyakoojo W, Kayima J, Freers J. Presenting features of newly diagnosed rheumatic heart disease patients in Mulago Hospital: a pilot study. Cardiovasc J Afr. 2013 Mar;24(2):28-33. doi: 10.5830/CVJA-2012-076.</citation>
    <PMID>23612950</PMID>
  </reference>
  <reference>
    <citation>Okello E, Wanzhu Z, Musoke C, Twalib A, Kakande B, Lwabi P, Wilson NB, Mondo CK, Odoi-Adome R, Freers J. Cardiovascular complications in newly diagnosed rheumatic heart disease patients at Mulago Hospital, Uganda. Cardiovasc J Afr. 2013 Apr;24(3):80-5. doi: 10.5830/CVJA-2013-004.</citation>
    <PMID>23736132</PMID>
  </reference>
  <reference>
    <citation>Beaton A, Okello E, Lwabi P, Mondo C, McCarter R, Sable C. Echocardiography screening for rheumatic heart disease in Ugandan schoolchildren. Circulation. 2012 Jun 26;125(25):3127-32. doi: 10.1161/CIRCULATIONAHA.112.092312. Epub 2012 May 24.</citation>
    <PMID>22626741</PMID>
  </reference>
  <reference>
    <citation>Steer AC, Kado J, Wilson N, Tuiketei T, Batzloff M, Waqatakirewa L, Mulholland EK, Carapetis JR. High prevalence of rheumatic heart disease by clinical and echocardiographic screening among children in Fiji. J Heart Valve Dis. 2009 May;18(3):327-35; discussion 336.</citation>
    <PMID>19557993</PMID>
  </reference>
  <reference>
    <citation>Engel ME, Haileamlak A, Zühlke L, Lemmer CE, Nkepu S, van de Wall M, Daniel W, Shung King M, Mayosi BM. Prevalence of rheumatic heart disease in 4720 asymptomatic scholars from South Africa and Ethiopia. Heart. 2015 Sep;101(17):1389-94. doi: 10.1136/heartjnl-2015-307444. Epub 2015 Jun 15.</citation>
    <PMID>26076935</PMID>
  </reference>
  <reference>
    <citation>Zühlke LJ, Beaton A, Engel ME, Hugo-Hamman CT, Karthikeyan G, Katzenellenbogen JM, Ntusi N, Ralph AP, Saxena A, Smeesters PR, Watkins D, Zilla P, Carapetis J. Group A Streptococcus, Acute Rheumatic Fever and Rheumatic Heart Disease: Epidemiology and Clinical Considerations. Curr Treat Options Cardiovasc Med. 2017 Feb;19(2):15. doi: 10.1007/s11936-017-0513-y. Review.</citation>
    <PMID>28285457</PMID>
  </reference>
  <reference>
    <citation>Reményi B, Wilson N, Steer A, Ferreira B, Kado J, Kumar K, Lawrenson J, Maguire G, Marijon E, Mirabel M, Mocumbi AO, Mota C, Paar J, Saxena A, Scheel J, Stirling J, Viali S, Balekundri VI, Wheaton G, Zühlke L, Carapetis J. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease--an evidence-based guideline. Nat Rev Cardiol. 2012 Feb 28;9(5):297-309. doi: 10.1038/nrcardio.2012.7. Review.</citation>
    <PMID>22371105</PMID>
  </reference>
  <reference>
    <citation>Beaton A, Lu JC, Aliku T, Dean P, Gaur L, Weinberg J, Godown J, Lwabi P, Mirembe G, Okello E, Reese A, Shrestha-Astudillo A, Bradley-Hewitt T, Scheel J, Webb C, McCarter R, Ensing G, Sable C. The utility of handheld echocardiography for early rheumatic heart disease diagnosis: a field study. Eur Heart J Cardiovasc Imaging. 2015 May;16(5):475-82. doi: 10.1093/ehjci/jeu296. Epub 2015 Jan 5.</citation>
    <PMID>25564396</PMID>
  </reference>
  <reference>
    <citation>Weinberg J, Beaton A, Aliku T, Lwabi P, Sable C. Prevalence of rheumatic heart disease in African school-aged population: Extrapolation from echocardiography screening using the 2012 World Heart Federation Guidelines. Int J Cardiol. 2016 Jan 1;202:238-9. doi: 10.1016/j.ijcard.2015.08.128. Epub 2015 Sep 12.</citation>
    <PMID>26402451</PMID>
  </reference>
  <reference>
    <citation>Roberts K, Colquhoun S, Steer A, Reményi B, Carapetis J. Screening for rheumatic heart disease: current approaches and controversies. Nat Rev Cardiol. 2013 Jan;10(1):49-58. doi: 10.1038/nrcardio.2012.157. Epub 2012 Nov 13. Review.</citation>
    <PMID>23149830</PMID>
  </reference>
  <reference>
    <citation>Karthikeyan G. Measuring and reporting disease progression in subclinical rheumatic heart disease. Heart Asia. 2016 Nov 28;8(2):74-75. eCollection 2016.</citation>
    <PMID>27942046</PMID>
  </reference>
  <reference>
    <citation>Nascimento BR, Nunes MC, Lopes EL, Rezende VM, Landay T, Ribeiro AL, Sable C, Beaton AZ. Rheumatic heart disease echocardiographic screening: approaching practical and affordable solutions. Heart. 2016 May;102(9):658-64. doi: 10.1136/heartjnl-2015-308635. Epub 2016 Feb 18. Review.</citation>
    <PMID>26891757</PMID>
  </reference>
  <reference>
    <citation>Steer AC, Romani L, Kaldor JM. Mass Drug Administration for Scabies Control. N Engl J Med. 2016 Apr 28;374(17):1690. doi: 10.1056/NEJMc1600495.</citation>
    <PMID>27119244</PMID>
  </reference>
  <reference>
    <citation>Engelman D, Okello E, Beaton A, Selnow G, Remenyi B, Watson C, Longenecker CT, Sable C, Steer AC. Evaluation of Computer-Based Training for Health Workers in Echocardiography for RHD. Glob Heart. 2017 Mar;12(1):17-23.e8. doi: 10.1016/j.gheart.2015.12.001. Epub 2016 Mar 16.</citation>
    <PMID>26994642</PMID>
  </reference>
  <reference>
    <citation>Ploutz M, Lu JC, Scheel J, Webb C, Ensing GJ, Aliku T, Lwabi P, Sable C, Beaton A. Handheld echocardiographic screening for rheumatic heart disease by non-experts. Heart. 2016 Jan;102(1):35-9. doi: 10.1136/heartjnl-2015-308236. Epub 2015 Oct 5.</citation>
    <PMID>26438784</PMID>
  </reference>
  <reference>
    <citation>Lopes EL, Beaton AZ, Nascimento BR, Tompsett A, Dos Santos JP, Perlman L, Diamantino AC, Oliveira KK, Oliveira CM, Nunes MDCP, Bonisson L, Ribeiro AL, Sable C; Programa de RastreamentO da Valvopatia Reumática (PROVAR) investigators. Telehealth solutions to enable global collaboration in rheumatic heart disease screening. J Telemed Telecare. 2018 Feb;24(2):101-109. doi: 10.1177/1357633X16677902. Epub 2016 Nov 4.</citation>
    <PMID>27815494</PMID>
  </reference>
  <reference>
    <citation>Zhang W, Okello E, Nyakoojo W, Lwabi P, Mondo CK. Proportion of patients in the Uganda rheumatic heart disease registry with advanced disease requiring urgent surgical interventions. Afr Health Sci. 2015 Dec;15(4):1182-8. doi: 10.4314/ahs.v15i4.17.</citation>
    <PMID>26958019</PMID>
  </reference>
  <reference>
    <citation>Okello E, Longenecker CT, Beaton A, Kamya MR, Lwabi P. Rheumatic heart disease in Uganda: predictors of morbidity and mortality one year after presentation. BMC Cardiovasc Disord. 2017 Jan 7;17(1):20. doi: 10.1186/s12872-016-0451-8.</citation>
    <PMID>28061759</PMID>
  </reference>
  <reference>
    <citation>Beaton A, Okello E, Aliku T, Lubega S, Lwabi P, Mondo C, McCarter R, Sable C. Latent rheumatic heart disease: outcomes 2 years after echocardiographic detection. Pediatr Cardiol. 2014 Oct;35(7):1259-67. doi: 10.1007/s00246-014-0925-3. Epub 2014 May 15.</citation>
    <PMID>24827080</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Research Institute</investigator_affiliation>
    <investigator_full_name>Andrea Beaton</investigator_full_name>
    <investigator_title>Cardiologist, Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>echocardiography</keyword>
  <keyword>penicillin prophylaxis</keyword>
  <keyword>intramuscular benzathine penicillin G</keyword>
  <keyword>benzathine penicillin G</keyword>
  <keyword>low-resource setting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Rheumatic Heart Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penicillins</mesh_term>
    <mesh_term>Penicillin G</mesh_term>
    <mesh_term>Penicillin G Benzathine</mesh_term>
    <mesh_term>Penicillin G Procaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

